Cutaneous leukocytoclastic vasculitis due to anti-tuberculosis medications, rifampin and pyrazinamide.
- Author:
Joo Hee KIM
1
;
Jun Il MOON
;
Jeong Eun KIM
;
Gil Soon CHOI
;
Hae Sim PARK
;
Young Min YE
;
Hyunee YIM
Author Information
- Publication Type:Case Report
- Keywords: Cutaneous leukocytoclastic vasculitis; rifampin; pyrazinamide; pulmonary tuberculosis
- MeSH: Adrenal Cortex Hormones; Adult; Ethambutol; Exanthema; Extremities; Forearm; Forehead; Histamine Antagonists; Humans; Isoniazid; Male; Prednisolone; Pruritus; Purpura; Pyrazinamide; Rifampin; Skin; Tuberculosis, Pulmonary; Urticaria; Vasculitis; Vasculitis, Leukocytoclastic, Cutaneous
- From:Allergy, Asthma & Immunology Research 2010;2(1):55-58
- CountryRepublic of Korea
- Language:English
- Abstract: Anti-tuberculosis drugs frequently result in cutaneous adverse reactions, including pruritus, maculopapular exanthems, and urticaria. However, anti-tuberculosis drug-associated cutaneous leukocytoclastic vasculitis (CLV) has been rarely reported. We describe a case of CLV induced by rifampin and pyrazinamide. A 38-year-old male had been diagnosed with pulmonary tuberculosis two months ago and then he started standard anti-tuberculosis therapy with isoniazid, rifampin, ethambutol, and pyrazinamide. Purpuric lesions developed in the extremities after 1.5 months of anti-tuberculosis medication; the lesions progressively spread over the entire body. Histopathology of the purpuric skin lesion was consistent with leukocytoclastic vasculitis. The skin lesion improved after cessation of anti-tuberculosis medications and treatment with oral corticosteroids and antihistamines. Anti-tuberculosis drugs were rechallenged one at a time over 3 days. Purpura recurred on the right forearm and forehead after taking 300 mg of rifampin. The skin lesion disappeared after taking oral prednisolone. Finally, 1,500 mg of pyrazinamide was readministrated, and then purpuric lesions recurred on both forearms. This report describes a case of leukocytoclastic vasculitis secondary to rifampin and pyrazinamide therapy.
